A Study to Test the Activity and Safety of Vixarelimab in Patients with Moderate to Severe Active Ulcerative Colitis

2024-516287-29-00 Protocol GA45735 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 26 Feb 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol GA45735

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 24
Countries 1
Sites 1

Moderate to Severe Active Ulcerative Colitis (UC)

Key facts

Sponsor
Genentech Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
26 Feb 2025 → ongoing
Decision date (initial)
2024-12-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Moderate to Severe Active Ulcerative Colitis (UC)

VersionLevelCodeTermSystem organ class
20.0 PT 10009900 Colitis ulcerative 100000004856

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Genentech Inc.

Sponsor organisation
Genentech Inc.
Address
1 Dna Way
City
South San Francisco
Postcode
94080-4918
Country
United States

Scientific contact point

Organisation
Genentech Inc.
Contact name
US Program Manager Product Development Regulatory

Public contact point

Organisation
Genentech Inc.
Contact name
US Program Manager Product Development Regulatory

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 24 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
Charite Research Organisation GmbH
N/A, Chariteplatz 1, Mitte, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-02-26 2025-03-11

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-18 Germany Acceptable
2024-12-18
2024-12-18
2 SUBSTANTIAL MODIFICATION SM-1 2025-03-06 Germany Acceptable 2025-04-04
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-22 Germany Acceptable 2025-10-22